Co-amoxiclav detailed information

Co-amoxiclav detailed information

Combination of
Amoxicillin	Penicillin antibiotic
Potassium clavulanate	Beta-lactamase inhibitor
[[{{{component3}}}]]	? Class
[[{{{component4}}}]]	? Class
[[{{{component5}}}]]	? Class
Clinical data
ATC code	J01CR02 (WHO)
Identifiers
CAS Number	74469-00-4
PubChem CID	6435924
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}

WikiDoc Resources for Co-amoxiclav detailed information
Articles
Most recent articles on Co-amoxiclav detailed information Most cited articles on Co-amoxiclav detailed information Review articles on Co-amoxiclav detailed information Articles on Co-amoxiclav detailed information in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Co-amoxiclav detailed information Images of Co-amoxiclav detailed information Photos of Co-amoxiclav detailed information Podcasts & MP3s on Co-amoxiclav detailed information Videos on Co-amoxiclav detailed information
Evidence Based Medicine
Cochrane Collaboration on Co-amoxiclav detailed information Bandolier on Co-amoxiclav detailed information TRIP on Co-amoxiclav detailed information
Clinical Trials
Ongoing Trials on Co-amoxiclav detailed information at Clinical Trials.gov Trial results on Co-amoxiclav detailed information Clinical Trials on Co-amoxiclav detailed information at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Co-amoxiclav detailed information NICE Guidance on Co-amoxiclav detailed information NHS PRODIGY Guidance FDA on Co-amoxiclav detailed information CDC on Co-amoxiclav detailed information
Books
Books on Co-amoxiclav detailed information
News
Co-amoxiclav detailed information in the news Be alerted to news on Co-amoxiclav detailed information News trends on Co-amoxiclav detailed information
Commentary
Blogs on Co-amoxiclav detailed information
Definitions
Definitions of Co-amoxiclav detailed information
Patient Resources / Community
Patient resources on Co-amoxiclav detailed information Discussion groups on Co-amoxiclav detailed information Patient Handouts on Co-amoxiclav detailed information Directions to Hospitals Treating Co-amoxiclav detailed information Risk calculators and risk factors for Co-amoxiclav detailed information
Healthcare Provider Resources
Symptoms of Co-amoxiclav detailed information Causes & Risk Factors for Co-amoxiclav detailed information Diagnostic studies for Co-amoxiclav detailed information Treatment of Co-amoxiclav detailed information
Continuing Medical Education (CME)
CME Programs on Co-amoxiclav detailed information
International
Co-amoxiclav detailed information en Espanol Co-amoxiclav detailed information en Francais
Business
Co-amoxiclav detailed information in the Marketplace Patents on Co-amoxiclav detailed information
Experimental / Informatics
List of terms related to Co-amoxiclav detailed information

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Co-amoxiclav is the British Approved Name, in the British Pharmacopoeia, for the combination antibiotic containing Amoxicillin (as either trihydate or the sodium salt) and Clavulanic acid (as Potassium clavulanate). This name, unlike co-trimoxazole, has not been widely adopted internationally and the combination product is usually referred to by various names such as amoxicillin with clavulanic acid or amoxicillin+clavulanate or simply by the trade name. Co-amoxiclav is currently marketed under various trade names including Augmentin (GlaxoSmithKline formerly Beecham), and for veterinary use as Clavamox/Synulox (Pfizer) and Clavaseptin (Vétoquinol).

The combination of amoxicillin, a β-lactam antibiotic; with clavulanic acid, a β-lactamase inhibitor; results in an antibiotic with an increased spectrum of action and restored efficacy against β-lactamase producing amoxicillin-resistant bacteria.

Dosage

The proportions of the two constituents are expressed as x/y where x and y are the strengths in milligrams of amoxicillin and clavulanic acid respectively. However, the branded products indicate their strengths as the total combined antibiotic quantity, hence co-amoxiclav 250/125 ≡ Augmentin 375 and contains 250 mg of amoxicillin with 125 mg of clavulanic acid.

Standard adult dosages for respiratory tract, urinary, abdominal and dental infections as well as cellulitis and animal bites is co-amoxiclav 250/125 (one tablet Augmentin 375) taken every 8 hours, which may be doubled in severe infections (either as two tablets at a time of Augmentin 375, or a single tablet of co-amoxiclav 500/125 ≡ Augmentin 625). In the US, Augmentin XR (co-amoxiclav 1000/62.5) is marketed for use in community acquired pneumonia with two tablets taken twice a day (giving 4000 mg total daily dose of amoxicillin).

Dosages for children are also given three times a day using suspensions containing co-amoxiclav 250/62 in each 5 mL (Augmentin '250/62 SF') for those between the ages of 6 - 12 years and co-amoxiclav 125/31 (Augmentin '125/31 SF') for those between the ages of 1 - 6 years. A more concentrated solution, co-amoxiclav 400/57 (Augmentin Duo), may be administered more conveniently just twice daily to children from as young as 2 months of age; quantities are based on body weight with 2.5 mL from the age of 2 years and 5 mL after the age of 6 years.

Side effects

Amongst the possible side-effects of this medication are diarrhea, vomiting and a few other conditions. These do not usually require medical attention. However, if the patient experiences an allergic reaction to the medication, jaundice, fever or severe diarrhoea, it is necessary to contact a doctor immediately. As with all antimicrobial agents, pseudomembranous colitis has been associated with the use of amoxicillin-clavulanate.

Amoxicillin is a member of the penicillin family of antibiotics, and therefore should not be taken by patients allergic to penicillin.

Veterinary use

The amoxicillin/clavulanic acid combination is also used in the treatment of, amongst other infections, periodontitis in dogs and skin infections in cats. The preparation for veterinary use is commonly marketed under the trade names Clavaseptin, and Clavamox (or Synulox in Europe).

Other Notes

Liquid co-amoxiclav must be refrigerated to maintain effectiveness. Many patients find the taste of Augmentin extremely unpleasant.

References

• British National Formulary 45 March 2003

External links

• Augmentin Homepage